PCBL Chemical Limited (formerly Phillips Carbon Black Limited)

All figures consolidated, INR crore unless stated. Primary sources: company audited results (FY25, FY26), ICICI Direct Q4FY26 result update (3 May 2026, compiling company data), StockAnalysis.com income statement (company data, INR million converted to crore), IDBI Capital report (Aug 2024).

Income statement

Notes: EBITDA per ICICI Direct; company-reported EBITDA was INR 1,384 crore for FY25 and INR 1,081 crore for FY26 (including other income), and StockAnalysis shows different EBITDA definitions (FY26 INR 1,043 crore). FY26 PBT is after a INR 12.45 crore exceptional charge (standalone) for the new Labour Codes notified 21 Nov 2025. FY26 diluted EPS per company INR 5.15; one aggregator (Fyers) shows INR 5.03; ICICI shows 5.0.

Margins and growth (derived)

Revenue CAGR: FY22–FY26 ≈16.5% (derived); FY21–FY26 25.2% (ICICI Direct; FY21 revenue INR 2,659.5 crore).

Commentary. The five-year record shows two distinct phases. FY22–FY24 was a volume-and-spread upcycle: carbon black volumes rose from 454 KT to 532 KT, EBITDA per tonne climbed to a record INR 19,322 in FY24, and EBITDA margin peaked at 16.2%. FY25 revenue jumped 31% almost entirely because of Aquapharm's first full year, but net profit fell 11.5% as acquisition-related interest cost (finance cost rose from INR 177 crore to INR 452 crore) and depreciation absorbed the incremental EBITDA. FY26 was the inflection downwards: carbon black EBITDA per tonne collapsed 26% to INR 14,222 (ICICI Direct) as Chinese and Russian competition, domestic overcapacity, US tariffs on Indian exports and feedstock volatility squeezed spreads, while Aquapharm stagnated. Net profit fell 54.5% to INR 198 crore, its lowest in at least six years. Gross margin held at ~30%, indicating the pressure came through lower absolute spreads and higher fixed/interest costs rather than percentage gross margin.

Quarterly trajectory (FY26–Q1 FY27)

Sources: company results via 5paisa/Kotak/Scanx; EBITDA per ICICI Direct (company-reported EBITDA: Q1 FY26 INR 325 crore, Q2 FY26 INR 278 crore, Q4 FY26 INR 248 crore, Q1 FY27 INR 400 crore). Q1 FY27 EBITDA included ≈INR 70 crore inventory gains; adjusted EBITDA ≈INR 340 crore and adjusted EBITDA/t ≈INR 18,430 (ICICI Securities; Nuvama). Q2 FY26 EBITDA/t is approximate (~INR 14,250, ICICI Direct).

Carbon black operating KPIs

Source: ICICI Direct assumptions table, May 2026 (compiled from company disclosures). Specialty share of volume rose from 7.6% (FY22) to 11.3% (FY26).

Balance sheet

Sources: ICICI Direct consolidated balance sheet (FY25, FY26P); company net worth per audited results. The gap between ICICI shareholders' funds and company "net worth" reflects definitional differences (treatment of warrant money, reserves and minority interest); both are shown. Short-term vs long-term split is available only on a standalone basis: standalone non-current borrowings INR 2,269.3 crore (FY25) → INR 1,707.6 crore (FY26); current borrowings INR 985.7 crore → INR 818.9 crore.

Cash flow

Source: ICICI Direct cash flow statement. FY26 OCF benefited from a INR 656 crore release from current assets as falling feedstock prices cut inventory and receivables. Standalone OCF was INR 1,052.6 crore (FY26) vs INR 565.1 crore (FY25).

Ratios

Sources: ICICI Direct (ROE, ROCE, ROIC, ratios, working capital days). ROA and asset turnover derived using total assets = capital employed + current liabilities from the ICICI balance sheet. Interest coverage derived. Standalone ratios per audited results differ: debt/equity 0.87 (FY25) and 0.62 (FY26); current ratio 0.95 and 0.78; interest service coverage 3.57 and 2.59.

Commentary on balance sheet and returns. The Aquapharm acquisition transformed PCBL from a low-leverage company (interest coverage above 20x in FY22) to a moderately levered one (net debt/EBITDA ~3.7x in FY25, rising to ~4.4x in FY26 on lower EBITDA despite INR 455 crore of debt reduction). Management's Vision 2030 targets net debt/EBITDA below 1x. ROE has halved from mid-teens to 5.4% and ROIC (8.4% in FY26) is well below the company's stated internal hurdle of 17–18% (IDBI Capital, Jul 2025). Both rating agencies moved outlooks to Negative in 2026, and the company sought and obtained debenture-holder approval in March 2026 to defer a financial covenant, a clear signal that FY26 metrics breached original thresholds. FY26's working-capital release and capex discipline did produce the best free cash flow in the period shown.

Management guidance (FY27)

High single-digit carbon black volume growth; carbon black EBITDA per tonne up 14–15% over FY26 (≈INR 16,500–17,000/t); double-digit consolidated EBITDA growth; Aquapharm revenue +20–25% with an INR 75 crore quarterly EBITDA run-rate target; capex ≈INR 300 crore; a softer Q2 FY27 followed by H2 recovery.

Street expectations

Broker estimates span FY27E EPS of ≈INR 10.3 (ICICI Direct, May 2026) to ≈INR 12.7 (Kotak, post-Q1) and FY28E EPS of ≈INR 16.3–18.2. ICICI Direct projects FY27E revenue of INR 10,213 crore and EBITDA of INR 1,315 crore, and FY28E EBITDA of INR 1,738 crore; Prabhudas Lilladher expects carbon black volume growth of ~9% in FY27 and ~5% in FY28. Prabhudas Lilladher's pre-season estimate for Q2 FY27 (published Oct 2026) projected net sales of about INR 2,057 crore, EBITDA of about INR 305 crore and PAT of about INR 81 crore, implying a sharp sequential normalisation from Q1.

Bull case

1. Spread recovery from a trough: FY26 CB EBITDA/t of INR 14,222 is ~26% below FY24–FY25 levels; even guided recovery to ~INR 17,000 on ~660–700 KT volume lifts carbon black EBITDA by roughly a quarter, and trade tailwinds (US tariff relief, reduced Russian supply) could push it higher.

2. Operating leverage on new capacity: 110 KT of capacity added in FY26–Q1 FY27 (TN 90 KT + Mundra 20 KT specialty) is already built, so volume growth requires little incremental capex (FY27 capex only ≈INR 300 crore), supporting deleveraging from ≈4.4x.

3. Option value in battery materials: ECMS-backed acetylene black and a running nano-silicon pilot give exposure to India's cell-manufacturing build-out, with management targeting ≈INR 1,400 crore EBITDA from new verticals by FY30.

Bear case

1. Quality of Q1 earnings: ≈INR 70 crore of Q1 FY27 EBITDA came from inventory gains on a crude spike; a crude reversal would produce inventory losses and squeeze pass-through.

2. Aquapharm value destruction: EBITDA fell from ≈INR 417 crore (FY23, pre-deal) to INR 162 crore (FY26) on a INR 3,800 crore price; repeated guidance misses undermine the diversification thesis and leave goodwill risk.

3. Leverage and credit: both rating agencies on Negative outlook; a downgrade would raise funding costs while the AP greenfield (FY28 spend) and battery capex compete for cash.

Catalysts and monitorables (next 12 months)

• Q2 FY27 results (expected late Oct 2026): normalised EBITDA/t versus ~INR 17,000 guidance; volume recovery.

• Coal tar distillation investment decision.

• Commissioning and customer qualification of acetylene black (FY27 target) and nano-silicon sampling feedback.

• Aquapharm quarterly EBITDA versus INR 75 crore target.

• Rating actions by ICRA (annual review ~Feb 2027) and CARE.

• Net debt trajectory and January 2027 NCD amortisation.

• Trade policy: US tariff levels on Indian goods; anti-dumping actions on carbon black imports into India.

• AP greenfield environmental clearance and capex approval.

Analyst verdict

PCBL Chemical is at an earnings inflection point that the market has already partly priced. The shares rose almost 50% in the six months to September 2026, recovering from a March 2026 low near INR 245, as investors looked through FY26's 54% profit collapse toward a cyclical recovery in carbon black spreads. The underlying franchise is sound: PCBL is India's largest carbon black producer, it delivered record volumes even in FY26, its specialty mix is improving steadily, and captive power provides a cushion. The FY26 downturn was primarily a spread event driven by external factors (tariffs, Chinese and Russian competition, domestic overcapacity), and those factors show early signs of easing.

The problem is that the "specialty chemical" rerating thesis rests on two legs that have not yet proven themselves. Aquapharm, bought for INR 3,800 crore, earned INR 162 crore of EBITDA in FY26 and remains well short of both its pre-acquisition earnings and management's targets, while the debt raised to fund it has pushed leverage to ~4.4x and drawn Negative outlooks from both ICRA and CARE. The battery platform is strategically sensible and now policy-supported through ECMS, but it is pre-revenue and faces a well-funded domestic rival in Himadri.

At roughly 16x trailing EV/EBITDA and over 40x trailing earnings, the stock already discounts a solid FY27–FY28 recovery. Delivering guided EBITDA/t of ~INR 17,000 and Aquapharm's INR 75 crore quarterly run-rate would justify current levels with moderate upside; outperformance requires either spreads materially above guidance or tangible battery-materials revenue. Our balanced view is neutral-to-constructive: the cyclical floor appears to be in, but the risk/reward is now dependent on execution at Aquapharm and on deleveraging. Investors should prioritise Q2 FY27 normalised EBITDA/t, Aquapharm progress and credit-rating actions as the decisive signals over the next two to three quarters.

Prepared from public information available as of 7 October 2026.